Multiple System Atrophy Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight's "Multiple System Atrophy Pipeline Insight, 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in the Multiple System Atrophy pipeline landscape. It covers the Multiple System Atrophy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Multiple System Atrophy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Multiple System Atrophy Pipeline. Dive into DelveInsight's comprehensive report today! @ Multiple System Atrophy Pipeline Outlook- https://www.delveinsight.com/sample-request/multiple-system-atrophy-msa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Multiple System Atrophy Pipeline Report
• In May 2025, Teva Branded Pharmaceutical Products R&D Inc. announced study is to evaluate the efficacy of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA). A secondary objective of the study is to evaluate specific efficacy parameters of TEV-56286. Another secondary objective is to evaluate the safety and tolerability of TEV-56286.
• In May 2025, H. Lundbeck A/S conducted a study will consist of a double-blind period (DBP) and will include an optional open-label treatment extension (OLE) period. Participants in the DBP will be randomized to Lu AF82422 or placebo (2:1). All participants entering the OLE will receive Lu AF82422 during the OLE.
• In May 2025, PepGen Inc organized a study is to learn about the effects of an investigational medicine, PGN-EDODM1, to see how safe and tolerable multiple administrations of PGN-EDODM1 are for people with myotonic dystrophy type 1 (DM1) compared to placebo.
• DelveInsight's Multiple System Atrophy Pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Multiple System Atrophy treatment.
• The leading Multiple System Atrophy Companies such as Theravance Biopharma, Alterity Therapeutics, AskBio, Kainos Medicines, CORESTEM Inc., ProMIS Neuroscience, H. Lundbeck A/S and others.
• Promising Multiple System Atrophy Pipeline Therapies such as TEV-56286, Lu AF82422, Verdiperstat, TAK-341, ATH434, Safinamide Methanesulfonate, Rasagiline Mesylate and others.

Stay ahead with the most recent pipeline outlook for Multiple System Atrophy. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Multiple System Atrophy Treatment Drugs- https://www.delveinsight.com/sample-request/multiple-system-atrophy-msa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Multiple System Atrophy Emerging Drugs Profile
• Lu AF82422: H. Lundbeck A/S
Lu AF82422 is a human monoclonal antibody (mAb) that recognizes and binds to all major forms of extracellular α-syn and thereby is believed to prevent uptake and inhibit seeding of aggregation. Lu AF82422 has an active Fc region, which may increase immune-mediated clearance of α-syn/mAb complexes through microglia mediated uptake. Lu AF82422 is being developed by Lundbeck under a joint research and licensing agreement between Lundbeck and Genmab A/S. The drug is currently investigated in Phase III clinical trial for MSA patients.

• ATH434: Alterity Therapeutics
ATH434, is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. ATH434 has been shown preclinically to reduce α-synuclein pathology and preserve neuronal function by restoring normal iron balance in the brain. As an iron chaperone, it has excellent potential to treat Parkinson's disease as well as various Parkinsonian disorders such as Multiple System Atrophy (MSA). ATH434 successfully completed Phase I studies demonstrating the agent is well tolerated and achieved brain levels comparable to efficacious levels in animal models of MSA. ATH434 is currently being studied in two clinical trials: Study ATH434-201 is a randomized, double-blind, placebo-controlled Phase II clinical trial in patients with early-stage MSA and Study ATH434-202 is an open-label Phase II Biomarker trial in patients with more advanced MSA. ATH434 has been granted Orphan drug designation for the treatment of MSA by the US FDA and the European Commission.

• AB-1005: AskBio
AB-1005 is an investigational gene therapy based on adeno-associated viral vector serotype 2 (AAV2) containing the human glial cell line-derived neurotrophic factor (GDNF) transgene, which allows for stable and continuous expression of GDNF in localized regions of the brain after direct neurosurgical injection with magnetic resonance imaging (MRI)-monitored convection enhanced delivery. GDNF is a homodimer that is a distantly related member of the transforming growth factor-β superfamily. In midbrain neuronal cell cultures, recombinant human GDNF promoted the survival and morphological differentiation of dopaminergic neurons and increased their high-affinity dopamine uptake.

The Multiple System Atrophy Pipeline Report Provides Insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Multiple System Atrophy with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Multiple System Atrophy Treatment.
• Multiple System Atrophy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Multiple System Atrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Multiple System Atrophy market

Explore groundbreaking therapies and clinical trials in the Multiple System Atrophy Marketed and Pipeline Drugs. Access DelveInsight's detailed report now! @ New Multiple System Atrophy Drugs- https://www.delveinsight.com/sample-request/multiple-system-atrophy-msa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Multiple System Atrophy Companies
Theravance Biopharma, Alterity Therapeutics, AskBio, Kainos Medicines, CORESTEM Inc., ProMIS Neuroscience, H. Lundbeck A/S and others.

Multiple System Atrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Multiple System Atrophy Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Unveil the future of Multiple System Atrophy Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Multiple System Atrophy Market Drivers and Barriers- https://www.delveinsight.com/sample-request/multiple-system-atrophy-msa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Multiple System Atrophy Pipeline Report
• Coverage- Global
• Multiple System Atrophy Companies- Theravance Biopharma, Alterity Therapeutics, AskBio, Kainos Medicines, CORESTEM Inc., ProMIS Neuroscience, H. Lundbeck A/S and others.
• Multiple System Atrophy Pipeline Therapies- TEV-56286, Lu AF82422, Verdiperstat, TAK-341, ATH434, Safinamide Methanesulfonate, Rasagiline Mesylate and others.
• Multiple System Atrophy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Multiple System Atrophy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Multiple System Atrophy Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Multiple System Atrophy Companies, Key Products and Unmet Needs- https://www.delveinsight.com/sample-request/multiple-system-atrophy-msa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Introduction
2. Executive Summary
3. Multiple System Atrophy: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Multiple System Atrophy- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Lu AF82422: H. Lundbeck A/S
9. Drug profiles in the detailed report.....
10. Mid Stage Products (Phase II)
11. ATH434: Alterity Therapeutics
12. Drug profiles in the detailed report.....
13. Early Stage Products (Phase I)
14. AB-1005: AskBio
15. Drug profiles in the detailed report.....
16. Preclinical and Discovery Stage Products
17. Product Name: Company Name
18. Inactive Products
19. Multiple System Atrophy Key Companies
20. Multiple System Atrophy Key Products
21. Multiple System Atrophy- Unmet Needs
22. Multiple System Atrophy- Market Drivers and Barriers
23. Multiple System Atrophy- Future Perspectives and Conclusion
24. Multiple System Atrophy Analyst Views
25. Multiple System Atrophy Key Companies
26. Appendix

List of Top Selling Market Research Reports in 2025

Radiation retinopathy market- https://www.delveinsight.com/sample-request/radiation-retinopathy-market
Immune checkpoints activators market- https://www.delveinsight.com/report-store/immune-checkpoint-inhibitors-market
Cystic fibrosis Market- https://www.delveinsight.com/report-store/cystic-fibrosis-market
Palmoplantar pustulosis market- https://www.delveinsight.com/report-store/palmoplantar-pustulosis-market
Smoking cessation market- https://www.delveinsight.com/report-store/smoking-cessation-and-nicotine-addiction-market
Surgical energy instruments market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
Tay-Sachs market- https://www.delveinsight.com/report-store/tay-sachs-disease-market
Attention deficit hyperactivity disorder market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Medical marijuana market- https://www.delveinsight.com/report-store/medical-marijuana-market
Open angle glaucoma market- https://www.delveinsight.com/report-store/glaucoma-market
Acute myeloid leukemia market- https://www.delveinsight.com/report-store/acute-myeloid-leukemia-aml-market
Asperger syndrome market- https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market
Bone growth stimulators market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Cardiogenic shock market- https://www.delveinsight.com/report-store/cardiogenic-shock-market
Pacemakers market- https://www.delveinsight.com/report-store/pacemakers-market
Pediatric brain tumor market- https://www.delveinsight.com/report-store/pediatric-brain-tumors-market
Pelizaeus-merzbacher disease market- https://www.delveinsight.com/report-store/pelizaeus-merzbacher-disease-market
Peritoneal carcinomatosis market- https://www.delveinsight.com/report-store/peritoneal-carcinomatosis-pc-market
Pipeline assessment services- https://www.delveinsight.com/consulting/pipeline-assessment-services

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.